{"database": "lobbying", "table": "lobbying_activities", "rows": [[1615911, "b9060d1e-336f-46e3-bec2-9051451ef90c", "4T", "SLC HEALTH STRATEGIES, LLC", 401018877, "CUBIST PHARMACEUTICALS, INC.", 2014, "fourth_quarter", "PHA", "Implementation of the \"GAIN\" provisions/Title VIII of the Food and Drug Administration Safety and Innovation Act (FDASIA) - PL 112-144; antibiotic product development incentive, limited population antibiotic product (LPAD) and breakpoint legislation \nHR 3742 -- the Antibiotic Development to Advance Patient Treatment Act of 2013 \nH.R.4187 -- Developing an Innovative Strategy for Antimicrobial Resistant Microorganisms Act of 2014 \nantibiotic product incentives for possible inclusion in the House \"21st Century Cures\" effort", "HOUSE OF REPRESENTATIVES,SENATE", 60000, null, 0, 1, "2014-12-29T13:05:39.897000-05:00"]], "columns": ["id", "filing_uuid", "filing_type", "registrant_name", "registrant_id", "client_name", "filing_year", "filing_period", "issue_code", "specific_issues", "government_entities", "income_amount", "expense_amount", "is_no_activity", "is_termination", "received_date"], "primary_keys": ["id"], "primary_key_values": ["1615911"], "units": {}, "query_ms": 17.70278310868889, "source": "Federal Register API & Regulations.gov API", "source_url": "https://www.federalregister.gov/developers/api/v1", "license": "Public Domain (U.S. Government data)", "license_url": "https://www.regulations.gov/faq"}